FACTOR VII TAKEDA 600 UI/VIAL POLVO LIOFILIZADO PARA SOLUCIÓN INYECTABLE + SOLVENTE I.V. Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

factor vii takeda 600 ui/vial polvo liofilizado para solución inyectable + solvente i.v.

takeda manufacturing austria ag - factor vii - factor vii....600 ui / agua inyectable....10 ml

ADVATE 500 IU Israel - English - Ministry of Health

advate 500 iu

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - powder for solution for injection - octocog alfa (antihemophilic factor recombinant) 500 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

ADVATE 1000 IU Israel - English - Ministry of Health

advate 1000 iu

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - powder for solution for injection - octocog alfa (antihemophilic factor recombinant) 1000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

ADVATE 1500 IU Israel - English - Ministry of Health

advate 1500 iu

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - powder for solution for injection - octocog alfa (antihemophilic factor recombinant) 1500 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

ADVATE 2000 IU Israel - English - Ministry of Health

advate 2000 iu

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - powder for solution for injection - octocog alfa (antihemophilic factor recombinant) 2000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

ADVATE 3000 IU Israel - English - Ministry of Health

advate 3000 iu

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - powder for solution for injection - octocog alfa (antihemophilic factor recombinant) 3000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

ADVATE 250 IU Israel - English - Ministry of Health

advate 250 iu

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - powder for solution for injection - octocog alfa (antihemophilic factor recombinant) 250 iu/vial - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

NINLARO ixazomib (as citrate) 2.3mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

ninlaro ixazomib (as citrate) 2.3mg capsule blister pack

takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 3.29 mg (equivalent: ixazomib, qty 2.3 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

NINLARO ixazomib (as citrate) 3mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

ninlaro ixazomib (as citrate) 3mg capsule blister pack

takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 4.3 mg (equivalent: ixazomib, qty 3 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide black; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

NINLARO ixazomib (as citrate) 4mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

ninlaro ixazomib (as citrate) 4mg capsule blister pack

takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 5.7 mg (equivalent: ixazomib, qty 4 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.